SCHEMBL3158666

SCHEMBL3158666

O=C(c1ccc(S(=O)(=O)Nc2nccs2)cc1)N1CCCC(COc2cc(F)cc(F)c2)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 5/20 0.47
ALDH1A1 P00352 7/20 0.46
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
PKM P14618 1/20 0.46
CRHBP P24387 1/20 0.45
CRHR2 Q13324 1/20 0.45
SCN3A Q9NY46 2/20 0.45
TSHR P16473 2/20 0.43
HTT P42858 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
USP2 O75604 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
STAT3 P40763 1/20 0.43
HSD17B10 Q99714 1/20 0.43
MAPK1 P28482 1/20 0.43
SCN1A P35498 2/20 0.43
SCN8A Q9UQD0 2/20 0.43
CYP3A4 P08684 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3158834 0.93 KMT2A (0.51) SCN9AALDH1A1MEN1KMT2APKM
SCHEMBL3262317 0.89 ALDH1A1 (0.54) SCN9AALDH1A1MEN1KMT2APKM
SCHEMBL3163254 0.85 SCN9A (0.46) SCN9AALDH1A1MEN1KMT2APKM
SCHEMBL3169339 0.85 MEN1 (0.45) SCN9AALDH1A1MEN1KMT2APKM
SCHEMBL3169403 0.84 MEN1 (0.52) SCN9AALDH1A1MEN1KMT2ASCN3A
SCHEMBL3162724 0.83 SCN1A (0.50) SCN9AALDH1A1MEN1KMT2ACRHBP
SCHEMBL3172220 0.82 ALDH1A1 (0.56) ALDH1A1PKMCRHBPCRHR2HTT
SCHEMBL3163044 0.82 KMT2A (0.51) SCN9AALDH1A1MEN1KMT2APKM
SCHEMBL3153864 0.81 SCN1A (0.52) SCN9AALDH1A1KMT2APKMHTT
SCHEMBL3159058 0.81 MEN1 (0.47) SCN9AALDH1A1MEN1KMT2APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8741934-B2 Inhibitors of ion channels PFIZER LIMITED (GB) 2014-06-03 US disclosed
US-20130072471-A1 Inhibitors of Ion Channels MARRON BRIAN EDWARD (US) 2013-03-21 US disclosed
US-8357711-B2 Heterocyclic sulfonamides as inhibitors of ion channels PFIZER LIMITED (GB) 2013-01-22 US disclosed
EP-1995241-B1 Inhibitors of ion channels ICAGEN INC (US) 2010-03-17 EP disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed
EP-1995241-A1 Inhibitors of ion channels ICAgen, Incorporated (US) 2008-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072471-A1 Inhibitors of Ion Channels TRPV1, TRPV5, TRPA1 SCN9A 51/4885ALDH1A1 3113/4885MEN1 4729/4885
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 SCN9A 51/4885ALDH1A1 3113/4885MEN1 4729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.